<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Axelsen McGee | Activity</title>
	<link>https://www.catswannabecats.com/members/stewband0/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/stewband0/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Axelsen McGee.</description>
	<lastBuildDate>Wed, 01 Jul 2026 18:37:05 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">4b40a00be67438eab15b9e8e20bbb74a</guid>
				<title>Axelsen McGee posted an update: 86 (0.80-0.93)], and no effect in at-risk patients without [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23230/</link>
				<pubDate>Sun, 08 Jun 2025 07:39:11 -0400</pubDate>

									<content:encoded><![CDATA[<p>86 (0.80-0.93)], and no effect in at-risk patients without history of cardiovascular events . We observed a trend toward larger treatment benefits with SGLT-2i among patients with chronic kidney disease , and patients with uncontrolled diabetes for both GLP1-RA or SGLT-2i . Uncontrolled hypertension, obesity, gender, age and race did not appear to&hellip;<span class="activity-read-more" id="activity-read-more-23230"><a href="https://www.catswannabecats.com/activity/p/23230/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">767f565daa8a2d43104023a1c6a9e0d7</guid>
				<title>Axelsen McGee posted an update: 1%)] and the non-sarcopenia group [133/137 (97.1%)], [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/10937/</link>
				<pubDate>Sun, 01 Jun 2025 03:45:35 -0400</pubDate>

									<content:encoded><![CDATA[<p>1%)] and the non-sarcopenia group , P = 0.1778). The rate of perforation and the rate of delayed bleeding were not significantly different between the sarcopenia group and the non-sarcopenia group .</p>
<p> The presence of sarcopenia did not influence the rate of complications after ESD. Colorectal ESD is safe and effective even in patients wit&hellip;<span class="activity-read-more" id="activity-read-more-10937"><a href="https://www.catswannabecats.com/activity/p/10937/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a0a374513d842a350f5a9d6bb82cc458</guid>
				<title>Axelsen McGee became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/10392/</link>
				<pubDate>Sun, 01 Jun 2025 00:41:57 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>